Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SONN 
Sonnet Biotherapeutics Holdings Inc (SONN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: SONN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.49% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.51M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 1.34 | 52 Weeks Range 1.08 - 10.38 | Updated Date 11/4/2025 |
52 Weeks Range 1.08 - 10.38 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1405.87% |
Management Effectiveness
Return on Assets (TTM) -223.8% | Return on Equity (TTM) -714.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40779925 | Price to Sales(TTM) 27.51 |
Enterprise Value 40779925 | Price to Sales(TTM) 27.51 | ||
Enterprise Value to Revenue 40.78 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 6827352 | Shares Floating 6743545 |
Shares Outstanding 6827352 | Shares Floating 6743545 | ||
Percent Insiders 4.25 | Percent Institutions 3.45 |
Upturn AI SWOT
Sonnet Biotherapeutics Holdings Inc
Company Overview
History and Background
Sonnet Biotherapeutics Holdings, Inc. is a biotechnology company focused on developing innovative targeted biologic drugs. Founded in 2011, it aims to address unmet needs in oncology and other disease areas by leveraging its Fully Human Albumin Binding (FHAB) technology.
Core Business Areas
- Oncology: Developing next-generation immunotherapies and targeted therapies for cancer treatment using the FHAB platform to improve drug delivery and efficacy.
Leadership and Structure
Pankaj Mohan serves as the Chief Executive Officer. The company operates with a functional organizational structure, with teams focused on research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- SON-1010: An IL-12-FHAB fusion protein in Phase 1 clinical trials for solid tumors. The competitive landscape includes IL-12 therapies from companies like Alkermes (ALKS). Revenue from this product is currently $0 as it is pre-commercialization.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, driven by innovation in drug development and increasing investment in immuno-oncology. The market is characterized by high risk and high reward, with significant regulatory hurdles and long development timelines.
Positioning
Sonnet Biotherapeutics is positioned as a player in the immuno-oncology space, focused on improving targeted drug delivery and reducing systemic toxicity. The competitive advantage comes from their FHAB technology which facilitates targetted delivery.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Sonnet Biotherapeutics is focused on capturing a portion of this market through targeted therapies.
Upturn SWOT Analysis
Strengths
- Proprietary FHAB technology
- Experienced leadership team
- Focus on immuno-oncology
- Potential for improved drug delivery
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Dependence on key partnerships
- High risk of clinical trial failure
Opportunities
- Expanding pipeline through strategic collaborations
- Advancing clinical programs to later stages
- Securing regulatory approvals for key drug candidates
- Attracting additional funding and investment
Threats
- Competition from established pharmaceutical companies
- Regulatory challenges and delays
- Clinical trial failures
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- ALKS
- BMY
- MRK
Competitive Landscape
Sonnet Biotherapeutics faces significant competition from established pharmaceutical companies with greater resources and more advanced clinical programs. Their competitive advantage lies in the unique FHAB technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pre-clinical and early clinical development progress, with minimal revenue generation.
Future Projections: Future growth hinges on successful clinical trials and potential partnerships or licensing agreements. Analyst projections are highly speculative.
Recent Initiatives: Recent initiatives include advancing SON-1010 through Phase 1 trials and exploring new FHAB applications.
Summary
Sonnet Biotherapeutics is a high-risk, high-reward biotechnology company focused on developing novel immunotherapies. Their FHAB technology offers potential advantages, but the company faces significant challenges including limited resources and competition. Clinical trial progress and securing partnerships will be crucial for their long-term success. Investors should be aware of the speculative nature of investing in early-stage biotech companies like Sonnet.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The biotechnology industry is highly volatile, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonnet Biotherapeutics Holdings Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2006-10-31 | Interim CEO & Director Mr. Raghu Rao | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.sonnetbio.com |
Full time employees 13 | Website https://www.sonnetbio.com | ||
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.